TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Hyperbaric Oxygen Therapy on Behavioral Measures of Short Term Memory, Learning, and Behavior in Children With Autism
Brief Summary: PURPOSE

The purpose of this investigation is to evaluate the cognitive and behavioral effects of Hyperbaric Oxygenation Therapy in children who present with a diagnosis of autism spectrum disorder.

HYPOTHESIS

1. Hyperbaric Oxygenation Therapy will be safe to use with children with autism.
2. Hyperbaric Oxygenation Therapy will have a statistically significant effect on the symptoms of autism.
3. Hyperbaric Oxygenation Therapy will have a clinically significant observable effect on the overt symptoms of autism.
4. The decreases in the symptoms of autism will correlate positively with the number of Hyperbaric Oxygenation Therapy sessions.
5. Treatment gains obtained from Hyperbaric Oxygenation Therapy will be maintained at follow-up, post 40 treatment sessions.

SPECIFIC AIMS

1. Provide further evidence for the safety of Hyperbaric Oxygenation Therapy in children with autism.
2. To quantitatively assess the effects of Hyperbaric Oxygenation Therapy on behavioral and cognitive symptoms of autism before, during, and after treatment.
3. Identify number of treatments required to reach therapeutic effects.
4. Identify the length and durability of treatment effect and maintenance.


Options:
A: Intervention Type: DRUG; Name: Hyperbaric Oxygen Therapy; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Hyperbaric Oxygen Therapy; Assigned to Arm(s): N/A
C: Arm Label: Treatment- HBOT; Type: EXPERIMENTAL; Interventions: Procedure: Hyperbaric Oxygen Therapy (HBOT) | Arm Label: control-HBOT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Hyperbaric Oxygen Therapy (HBOT); Assigned to Arm(s): Treatment- HBOT
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Hyperbaric Oxygen Treatment (HBOT) | Intervention Type: OTHER; Name: Hyperbaric Oxygen Treatment (HBOT); Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®.
Brief Summary: Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' measles-mumps-rubella (MMR) vaccine (Priorix®) and varicella vaccine (Varilrix®) in Germany \& Austria. Blood samples were collected at three time points during the follow-up period (Year 1, 2 \& 3). No new subjects will be enrolled in these follow-up phases of the study.


Options:
A: Arm Label: MMRV Group; Type: EXPERIMENTAL; Interventions: Biological: Priorix-tetra™ | Arm Label: OKAH Group; Type: EXPERIMENTAL; Interventions: Biological: Priorix™, Biological: Varilrix™ | Arm Label: MMR Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Priorix™ | Intervention Type: BIOLOGICAL; Name: Priorix-tetra™; Assigned to Arm(s): MMRV Group | Intervention Type: BIOLOGICAL; Name: Priorix™; Assigned to Arm(s): MMR Group, OKAH Group | Intervention Type: BIOLOGICAL; Name: Varilrix™; Assigned to Arm(s): OKAH Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: 7vPnC | Intervention Type: BIOLOGICAL; Name: 13-valent Pneumococcal Conjugate Vaccine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: BIOLOGICAL; Name: 7vPnC; Assigned to Arm(s): 4
C: Intervention Type: BIOLOGICAL; Name: MMRV; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: MMR (Priorix®); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Varicella (Varilrix®); Assigned to Arm(s): N/A
D: Arm Label: 13vPnC vaccine; Type: EXPERIMENTAL; Interventions: Biological: 13 valent pneumococcal conjugate vaccine | Arm Label: 7vPnC vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: 7vPnc pneumococcal conjugate vaccine | Intervention Type: BIOLOGICAL; Name: 13 valent pneumococcal conjugate vaccine; Assigned to Arm(s): 13vPnC vaccine | Intervention Type: BIOLOGICAL; Name: 7vPnc pneumococcal conjugate vaccine; Assigned to Arm(s): 7vPnC vaccine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
Brief Summary: The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Lucentis (Ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab (Lucentis) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab (Lucentis) | Intervention Type: DRUG; Name: Ranibizumab (Lucentis); Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Literacy Intervention for Korean Americans With High Blood Pressure (HBP)
Brief Summary: Many Korean Americans are at risk for developing high blood pressure. Low health literacy levels may play a role in this risk. The purpose of this study is to evaluate a literacy-focused program aimed at reducing blood pressure levels in older Korean Americans.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminders of medicines intake | Intervention Type: BEHAVIORAL; Name: SMS reminders of medicines intake; Assigned to Arm(s): Intervention
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Medication review | Arm Label: Observational arm; Type: OTHER; Interventions: Behavioral: Medication review | Intervention Type: BEHAVIORAL; Name: Medication review; Assigned to Arm(s): Intervention group, Observational arm
C: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Intervention Type: BEHAVIORAL; Name: Health Literacy-Focused High Blood Pressure Intervention; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Crohn's Disease (CD) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Brief Summary: The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied.


Options:
A: Arm Label: Dex 21-P; Type: EXPERIMENTAL; Interventions: Drug: Dex 21-P | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dex 21-P; Assigned to Arm(s): Dex 21-P | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tralokinumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tralokinumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: abatacept | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: abatacept; Type: OTHER; Interventions: Drug: abatacept | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): abatacept
D: Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: 0.5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP- 690 550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 10 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 3 mg BID | Intervention Type: DRUG; Name: CP- 690 550; Assigned to Arm(s): 0.5 mg BID | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo Controlled Methodology Study to Evaluate the Time of Onset of AntiDepressant Response in Subjects With Major Depressive Disorder
Brief Summary: Purpose of the study is to evaluate use of electronic diaries and voice acoustics for use in future depression clinical trial. Focus is on increased precision of measurement.


Options:
A: Arm Label: Arm 1 - 900 mg/day Idebenone; Type: EXPERIMENTAL; Interventions: Drug: Idebenone | Arm Label: Arm 2 - up to 2250 mg/day Idebenone; Type: EXPERIMENTAL; Interventions: Drug: Idebenone | Arm Label: Arm 3 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): Arm 1 - 900 mg/day Idebenone | Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): Arm 2 - up to 2250 mg/day Idebenone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3 - Placebo
B: Intervention Type: PROCEDURE; Name: electronic diary; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voice acoustics; Assigned to Arm(s): N/A
C: Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Drug: alpha-tocopherolquinone (A0001) | Arm Label: High Dose; Type: EXPERIMENTAL; Interventions: Drug: alpha-tocopherolquinone (A0001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: alpha-tocopherolquinone (A0001); Assigned to Arm(s): Low Dose | Intervention Type: DRUG; Name: alpha-tocopherolquinone (A0001); Assigned to Arm(s): High Dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine
Brief Summary: To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye.

It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.


Options:
A: Arm Label: intense; Type: EXPERIMENTAL; Interventions: Drug: Softacort | Arm Label: standard; Type: EXPERIMENTAL; Interventions: Drug: Softacort | Intervention Type: DRUG; Name: Softacort; Assigned to Arm(s): intense, standard
B: Intervention Type: DRUG; Name: Lotemax; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Restasis; Assigned to Arm(s): N/A
C: Arm Label: Lotemax with warm compress group; Type: EXPERIMENTAL; Interventions: Drug: topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage | Arm Label: warm compress only group; Type: ACTIVE_COMPARATOR; Interventions: Other: warm compress only group | Intervention Type: DRUG; Name: topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage; Assigned to Arm(s): Lotemax with warm compress group | Intervention Type: OTHER; Name: warm compress only group; Assigned to Arm(s): warm compress only group
D: Arm Label: KPI-121 0.25% Ophthalmic Suspension; Type: ACTIVE_COMPARATOR; Interventions: Drug: KPI-121 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KPI-121; Assigned to Arm(s): KPI-121 0.25% Ophthalmic Suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Vehicle

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (FA) intravitreal implants for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye. An additional objective is to compare the safety and efficacy of two doses of fluocinolone acetonide.


Options:
A: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
D: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (FA) intravitreal implants for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye. An additional objective is to compare the safety and efficacy of two doses of fluocinolone acetonide.


Options:
A: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
D: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (FA) intravitreal implants for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye. An additional objective is to compare the safety and efficacy of two doses of fluocinolone acetonide.


Options:
A: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
B: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
D: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Two Different Immunosuppression Protocols in Highly Sensitized Renal Transplant Recipients: Campath Induction With Tacrolimus Monotherapy vs Thymoglobulin Induction With Triple Drug Protocol.
Brief Summary: Comparison between Campath induction and monotherapy with Tacrolimus vs Thymoglobulin induction and triple drug maintenance using Tacrolimus, mycophenolate, and steroids.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Campath-1H | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Daclizumab | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Campath-1H; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): C
B: Arm Label: Group 1 Standard Immunosuppression; Type: N/A; Interventions: N/A | Arm Label: Group 2 Campath Immunosuppression; Type: N/A; Interventions: N/A
C: Arm Label: Campath-1H 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus | Arm Label: Campath-1H 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 20 mg | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 30 mg
D: Arm Label: Single-dose Thymoglobulin; Type: EXPERIMENTAL; Interventions: Biological: Single-dose rabbit Anti-thymocyte Globulin induction | Arm Label: Divided-dose Thymoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Biological: Divided-dose rabbit Anti-thymocyte Globulin induction | Intervention Type: BIOLOGICAL; Name: Single-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Single-dose Thymoglobulin | Intervention Type: BIOLOGICAL; Name: Divided-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Divided-dose Thymoglobulin

Answer: B